Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX? (neratinib) in South Korea
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma's drug NERLYNX in South Korea.
